Clinical role of FDG PET/CT for methotrexate-related malignant lymphoma

Clinical Nuclear Medicine

Volumn 36, Issue 7, 2011, Pages 533-537

  Minamimoto, Ryogo ^a   Ito, Kimiteru ^b   Kubota, Kazuo ^a   Morooka, Miyako ^a   Masuda Miyata, Yoko ^c   Hirai, Risen ^a   Kitahara, Hideaki ^a   Tanimura, Akira ^a   Hagiwara, Shotaro ^a   Miwa, Akiyoshi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c Iwai Medical Foundation   (Japan)

Author keywords

F 18 2 fluoro 2 deoxyglucose; lymphoma; methotrexate; positron emission tomography; rheumatoid arthritis

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; STEROID; VINBLASTINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CERVICAL LYMPHADENOPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; FEMALE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MALE; PERIPHERAL T CELL LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PSORIASIS VULGARIS; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; TREATMENT WITHDRAWAL;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 79958278273     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182177296     Document Type: Article

References (18)

1. Au WY, Ma ES, Choy C, et al. Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs. Am J Hematol. 2006;81:5-11. (Pubitemid 43077207)
2. Starkebaum G. Rheumatoid arthritis and lymphoma: risky business for B cells. J Rheumatol. 2007;34:243-246.
3. Starkebaum G. Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus? J Rheumatol. 2001; 28:2573-2575. (Pubitemid 33135636)
4. Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol. 1998;25:408-416. (Pubitemid 28109338)
5. Kamel OW, van de Rijn M, LeBrun DP, et al. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein- Barr virus and other features associated with immunosuppression. Hum Pathol. 1994;25:638-643. (Pubitemid 24230740)
6. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993; 328:1317-1321. (Pubitemid 23131374)
7. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14:1943-1949. (Pubitemid 26185470)
8. Ellman MH, Hurwitz H, Thomas C, et al. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 1991;18:1741-1743.
9. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419-1432.
10. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322-331.
11. Menke DM, Griesser H, Moder KG, et al. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol. 2000;113:212-218. (Pubitemid 30212552)
12. Feng WH, Cohen JI, Fischer S, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96:1691-1702. (Pubitemid 39585638)
13. Schöder H, Noy A, Gönen M, et al. Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:4643-4651. (Pubitemid 46224066)
14. Jerusalem G, Hustinx R, Beguin Y, et al. Evaluation of therapy for lymphoma. Semin Nucl Med. 2005;35:186-196. (Pubitemid 41138137)
15. Mackie GC, Pohlen JM. Methotrexate-induced pulmonary non-Hodgkin lymphoma. Clin Nucl Med. 2006;31:272-274. (Pubitemid 44310018)
16. Nguyen BD, Roarke MC, McCullough AE. Methotrexate-induced and Epstein- Barr virus-associated B-cell lymphoma of the spine: MR and PET/CT imaging. Clin Nucl Med. 2008;33:208-210. (Pubitemid 351301559)
17. Jankowitz RC, Ganon J, Blodgett T. A putative case of methotrexate-related lymphoma: clinical course and PET/CT findings. Case Report Med. 2009; 2009:469343.
18. Kubota K, Ito K, Morooka M, et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med. 2009;23:783-791.